EMUC15 - Resource Centre - Search Results


Survival data from an IQUO register study on the treatment of patients with prostate cancer with Degarelix in daily clinical practice

By: Geiges G.1, Eckert R.2, Eichenauer R.3, Harms T.4, König F.5, Rodemer G.6, Thösen C.7
Institutes: 1IQUO, Interessenverband Z Qualitätssicherung D Arbeit Niedergelassener Uro-Onkologen I Deutschland, Dept. of Urology, Berlin, 2Private practice, Dept. of Urology, Lutherstadt Eisleben, 3Urologikum Hamburg, Dept. of Urology, Hamburg, 4Private practice, Dept. of Urology, Cologne, 5Aturo Berlin, Dept. of Urology, Berlin, 6Group Practice For Oncology and Urology, Dept. of Urology, Wilhelmshaven, 7Ferring Arzneimittel GmbH, Kiel

Introduction & Objectives

Collection of data in daily clinical practice on the efficacy and safety of Degarelix in the treatment of patients with prostate cancer (PCa).

Material & Methods

Data of 1,010 Degarelix patients were collected. During the assessment, previous treatment, concomitant medication, stage and grade of tumour as well as alkaline phosphatase, testosterone and PSA-value, side-effects, and overall survival were documented. At the time of this assessment the maximum follow-up was 48 months.


The median overall survival was not yet reached. The 75% threshold for overall survival was reached for all patients after 149 weeks (176 vs. 132 weeks in the sub-groups of hormone-naive patients and patients with previous hormone treatment, respectively, Fig. 1).

In the sub-group of patients with previous LHRH agonist therapy, the median time to PSA progression was shorter (30 weeks, 75% threshold) than in the group without previous LHRH therapy (88 weeks, 75% threshold, Fig. 2). A higher proportion of patients with previous LHRH therapy experienced PSA progression (25%, n=114) as compared to patients without previous LHRH therapy (15%, n=86).

In the sub-group of metastatic patients, the median progression-free survival was 141 weeks. The median follow-up of the whole patient population was 128 weeks (32 months).

The mean prostate volume decreased from 37 ml at the beginning (n=85) to 30 ml after 3 months (19% decrease, n=25) and 26 ml after 6 months (30% decrease, n=16).

The most frequent side-effects were hot flushes (12.87%), erythema at the injection site (8.5%) and fatigue (5.25%).



Efficacy and safety of Degarelix were confirmed in routine daily practice. The median survival was not yet reached. The 75% threshold for the overall survival was reached after 37 months. Thus, these values are already above those reported in scientific literature for LHRH agonists at 25-31 months.

  • Type: Abstract
  • Date: 12-11-2015
  • Rating: 0,0
  • Views: 892
  • Event: 7th European Multidisciplinary Meeting on Urological Cancers
  • Nr: P068